Amelioration of bleomycin-induced lung fibrosis in hamsters by dietary supplementation with taurine and niacin: biochemical mechanisms. by Giri, SN et al.
UC Davis
UC Davis Previously Published Works
Title
Amelioration of bleomycin-induced lung fibrosis in hamsters by dietary supplementation 
with taurine and niacin: biochemical mechanisms.
Permalink
https://escholarship.org/uc/item/5qv107nf
Journal
Environmental health perspectives, 102 Suppl 10(SUPPL. 10)
ISSN
0091-6765
Authors
Giri, SN
Blaisdell, R
Rucker, RB
et al.
Publication Date
1994-12-01
DOI
10.1289/ehp.94102s10137
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Amelioration of Bleomycin-induced Lung
Fibrosis in Hamsters by Dietary
Supplementation with Taurine and Niacin:
Biochemical Mechanisms
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Dallas M. Hyde3
1Department of Molecular Biosciences, Division of Pharmacology and Toxicology; 2Department of Nutrition,
School of Veterinary Medicine; 3Department of Anatomy, Physiology and Cell Biology, School of Veterinary
Medicine, University of California, Davis, California
Interstitial pulmonary fibrosis induced by intratracheal instillation of bleomycin (BL) involves an excess production of reactive oxygen species,
unavailability of adequate levels of NAD and ATP to repair the injured pulmonary epithelium, and an overexuberant lung collagen reactivity followed
by deposition of highly cross-linked mature collagen fibrils resistant to enzymatic degradation. In the present study, we have demonstrated that
dietary supplementation with taurine and niacin offered almost complete protection against the lung fibrosis in a multidose BL hamster model. The
mechanisms for the protective effect of taurine and niacin are multifaceted. These include the ability of taurine to scavenge HOCI and stabilize the
biomembrane; niacin's ability to replenish the BL-induced depletion of NAD and ATP; and the combined effect of taurine and niacin to suppress all
aspects of BL-induced increases in the lung collagen reactivity, a hallmark of interstitial pulmonary fibrosis. It was concluded from the data pre-
sented at this Conference that the combined treatment with taurine and niacin, which offers a multipronged approach, will have great therapeutic
potential in the intervention of the development of chemically induced interstitial lung fibrosis in animals and humans. - Environ Health Perspect
102(Suppl 10):137-148 (1994)
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Introduction
Our understanding of pulmonary interac-
tion with the environment has been
markedly advanced over the last several
years. The lung is strategically located
between the external or outside and the
internal or systemic environments. Thus, it
is continuously exposed to an increasing
number of potentially harmful chemicals
found in our biosphere as well as to chemi-
cals entering the body following systemic
administration. Some of these chemicals
disrupt the delicate structure of the lung
during the initial phase of acute inflamma-
tion followed by an increase in pulmonary
connective tissue during the chronic phase
leading to interstitial pulmonary fibrosis.
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Interstitial pulmonary fibrosis is a crip-
pling disease that is characterized by an
excessive accumulation of collagen,
reduced gas exchange, and reduced lung
compliance (1). This disease is associated
with a high incidence of morbidity and
mortality and it may result from exposure
to a number of environmental or pharma-
ceutical agents (2). Some of the processes
leading to interstitial pulmonary fibrosis
from these various agents are understood
and some still are ill defined. Regardless of
the multifactorial origin, interstitial pul-
monary fibrosis is invariably accompanied
by an overexuberant repair process that is
characterized by an excess number of
fibroblasts (3), an absolute increase in lung
collagen, abnormality in the ultrastructural
appearance, and spatial distribution of col-
lagen types (4-6).
Bleomycin (BL), an antineoplastic
drug, is widely used in the treatment of
lymphoma and testicular and squamous
cell tumors (7) because of its minimal
hematopoietic toxicity or immunosuppres-
sive activity (8). Unfortunately, BL therapy
is complicated by a dose-dependent inter-
stitial pneumonitis that often progresses
into interstitial pulmonary fibrosis (8),
greatly limiting its use on a long-term
basis. Thus, the search for effective
antifibrotic agents is of a great significance
not only for elucidating the mechanisms
for BL-induced lung fibrosis, but in pre-
venting the development of lung fibrosis
induced by a variety of therapeutic agents.
Bleomycin produces pulmonary toxicity
that subsequently develops into fibrosis in
a wide variety of animal species (9). The
intratracheal (IT) instillation of BL in the
rodent, as a model of pulmonary fibrosis, is
frequently employed. A single IT instilla-
tion of BL in the rodent produces bio-
chemical changes and histologic lesions
that resemble interstitial pulmonary fibro-
sis as seen in humans (10). Consequently,
the IT instillation of BL in rats (11), mice
(12), and hamsters (13) provides a conve-
nient and reproducible method to expose
the lungs to high concentrations of BL in a
single dose that is fibrogenic and at the
same time devoid of toxicity to other
organs. However, the single BL dose model
is invariably associated with morbidity and
high mortality.
Our laboratory has recently developed a
multidose IT instillation BL hamster
model of pulmonary fibrosis (14). Using
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this model, we have investigated the effects
of dietary supplementation with taurine
and niacin against the BL-induced lung
fibrosis in hamsters. In this respect, we
have examined the various aspects of lung
collagen reactivity including collagen con-
tent, prolyl hydroxylase, lysyloxidase, and
collagenase activities, and collagen cross-
links and poly(ADP-ribose) polymerase
activity. Also examined were the protein
content and acid phosphatase activity, total
and differential cell counts in the bron-
choalveolar lavage fluid (BALF), lung vol-
ume, and histopathologic features of the
lung lesions.
Materials and Methods
Pathogen-free male golden Syrian hamsters
weighing 80 to 100 g were purchased from
Simonsen, Inc. (Gilroy, CA). Bleomycin
sulfate (Blenoxane) was a gift from Bristol
Laboratories (Syracuse, NY). Taurine and
niacin were obtained from Sigma Chemical
Company (St. Louis, MO). Tritiated (498
mCi/mmole) sodium borohydride and
[1]4C-acetic anhydride (25 mCi/mmole)
were purchased from Amersham (Arlington
Heights, IL). [4,5] 3H-Lysine (specific
activity 95 Ci/mmole) was obtained from
New England Nuclear (Boston, MA).
Other chemicals were reagent grade or
higher purity and obtained from standard
commercial sources.
Hamsters were acclimatized for a mini-
mum of 1 week prior to the experiment.
The facility provided filtered air, a constant
temperature and humidity, and a 12-
hr/12-hr light/dark cycle. Animal care was
in accordance with NIH guidelines for ani-
mal welfare.
Animals were fed ad libitum either pul-
verized Rodent Laboratory Chow 5001
(Purina Mills Inc., St. Louis, MO) or the
same pulverized rat chow containing 2.5%
taurine and 2.5% niacin (w/w). Animals
were fed these diets starting 4 days before
the first intratracheal instillation and con-
tinuing throughout the course of the exper-
iment. The hamsters were randomly placed
into four treatment groups: saline-instilled
fed control diet (SA), bleomycin-instilled
fed control diet (BL), bleomycin-instilled
fed taurine-niacin in diet (TNBL), and
saline-instilled fed taurine-niacin in diet
(TNSA). The animals were intratracheally
instilled with either three consecutive doses
of bleomycin sulfate in saline, or saline 1
week apart (2.5, 2.0, and 1.5 U/5 ml/kg)
under pentobarbital anesthesia (75-85
mg/kg) as described by Zia et al. (14).
The animals were sacrificed 1, 3, 4, and
8 weeks after the instillation of the last dose
of saline or BL. The lungs of animals
sacrificed at 3 weeks were subjected to BAL
and morphologic and morphometric analy-
sis as described in earlier papers (15,16). An
aliquot of the fluid was apportioned for total
and differential cell count (17). The
remaining BALF was centrifuged at 15OOg
for 20 min at 40C, and the resulting super-
natant was used for the measurement of pro-
tein (18) and acid phosphatase activity (19).
Morphologic and Morphometric
Analysis
After BAL and thoracotomy, the heart was
ligated at the base for isolation of the pul-
monary vasculature. The trachea was can-
nulated, and then both heart and lungs
were removed en bloc and weighed. The
lungs were fixed via the trachea at a pres-
sure of 30 cm of water with a cacodylate-
buffered glutaraldehyde-paraformaldehyde
fixative (400 mOsm). The cannula was
removed, the trachea was tied off, and the
lung and heart stored in fixative. Fixed
lung volumes were determined by their
buoyant weight in saline after dissection of
the heart and adjacent mediastinal tissue
(20). Before embedding the lung tissue,
the heart and all nonpulmonary tissue were
isolated by blunt dissection and removed.
Blocks of tissue were cut from at least two
sagittal slabs (2-3 mm thick) from the
right cranial, right caudal, and left lung
lobes of each lung. Each block was cut with
about a 1-cm2 face. These blocks were
dehydrated in a graded series of ethanol
and embedded in paraffin. Sections 5 pm
thick were cut from the paraffin blocks and
stained with hematoxylin and eosin. From
selected blocks, adjacent sections were cut
and stained with sirus red for specific stain-
ing of collagenous fibers (21). The volume
of parenchymal lesion within the lung was
estimated using point counting techniques
and a square lattice test system at a final
magnification of x160. All tissue on the
slides was counted. Parenchymal lesions
were defined as thickening of interalveolar
septa due to edematous swelling,
inflammatory cells or fibrosis associated
with hyperplastic epithelial cells, and some
airway inflammatory cells remaining after
lung lavage. The volume of parenchymal
lesion was calculated from the product of
the volume of the lung, the volume of
parenchyma per lung, and the volume of
lesion per parenchymal volume (22).
Preparation of Lung for Biochemical
Assays
The lungs of hamsters assigned to various
biochemical assays were first perfused in
situ with cold saline; all lung lobes were
removed and frozen in liquid nitrogen. The
lungs were stored at -80°C until the assays
were performed. Later, the frozen lungs
were thawed and homogenized in 0. IM
KCl, 0.02M Tris, pH 7.6, with a Polytron
homogenizer (Brinkmann Instruments,
Inc., Westbury, NY). The homogenate was
mixed thoroughly by repeated inversions
and the homogenate volumes (9-10 ml)
were recorded. The samples were aliquoted
and stored at -80°C, except for the samples
for malondialdehyde equivalent and colla-
gen assays that were processed for their
measurement on the same day the lungs
were homogenated. Enzyme assays were
performed on supernatant obtained by cen-
trifugation of the lung homogenate at
12,000g for 20 min at 40C unless specified
otherwise.
Determination of Hydroxyproline
and Prolyl Hydroxylase Activity. For lung
hydroxyproline assay, 1 ml of homogenate
was precipitated with 0.25 ml of ice-cold
50% (w/v) TCA and centrifuged and the
precipitate was hydrolyzed in 2 ml of 6 N
HCl for 18 hr at 110°F. [3H]Hydroxy-
proline (1 x105 dpm) was added to each
sample to determine recovery, and the
hydroxyproline content was measured by
the technique described by Woessner (23).
The preparation of prolyl hydroxylase sub-
strate (procollagen) and the method for the
prolyl hydroxylase assay were essentially as
described in our previous paper (24).
During the reaction, tritium is released in
stoichiometric proportion to prolyl hydrox-
ylation and 3H2O is used as a measure of
the enzyme activity. The enzyme activity
was determined as disintegrations per
minute of 3H20 released per total lung per
30 min and it is reported as percent of the
control.
Determination ofMalondialdehyde
Equivalent, and Superoxide Dismutase
Activity. Lung malondialdehyde equivalent
was estimated from the total amount of
thiobarbituric acid-reacting products in
unfractionated homogenate by the method
of Ohkawa et al. (25). SOD activity of the
supernatant of lung homogenate was deter-
mined from the rate at which it inhibits the
autooxidation of epinephrine to adreno-
chrome, as described by Misra and Fridovich
(26). The rate of formation of adreno-
chrome was 0.025 absorbance units/min at
480 nm in a Varian Cary 219 spectropho-
tometer (Beckman Instruments, Palo Alto,
CA). Under these defined conditions, the
amount of tissue required to inhibit the
rate of formation of adrenochrome by 50%
(i.e., rate of 0.0125 absorbance units/min)
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was defined to contain 1 unit of SOD
activity.
Determination ofLung Calcium and
Poly(ADP-ribose) Polymerase Activity.
For calcium determination, 1 ml of lung
homogenate was first deproteinized in a
final concentration of 10% (w/v) TCA on
ice. After centrifugation, the TCA super-
natant was decanted and its volume
recorded. The calcium content of the
supernatant was determined by inductively
coupled plasma (ICP) atomic emission spec-
trometry (27), using a model 3510 ICP
spectrometer (Applied Research
Laboratories, Sunland, CA). Lung
poly(ADP-ribose) polymerase activity was
determined by measuring the incorpora-
tion of [14C]ADP-ribose for 15 min at
37°C into an acid-insoluble product as
reported previously (28). The activity of
the enzyme is expressed as picomoles of[14C]ADP-ribose incorporated per total
lung per 15 min.
Determination ofLung Lysyl Oxidase
and CoUlagenase Activity. At the time of
assay, the frozen lungs were weighed and
pulverized in foil packages just after
immersion in liquid nitrogen. The pulver-
ized lung tissue was then quantitatively
transferred to a test tube, allowed to thaw
on ice, and a volume of ice-cold saline in
ml equal to the weight (in g) of the lung
was added. The tissue was then homoge-
nized for 30 sec in three bursts with a
Polytron (Brinkman) set to a medium
power setting. A 0.5-ml aliquot was
removed for collagenase assay and adjusted
to 100 mM Tris HCI buffer, pH 7.6, in 15
mM CaCl2 with lOx buffer. A 0.3-ml
aliquot was removed from the whole
homogenate for hydrolysis in 6 N HCl,
and subsequent hydroxyproline determina-
tion according to the procedure of
Woessner (23). The remaining volume of
homogenate was used for lysyl oxidase
assay.
Lysyl oxidase substrate was prepared
according to the procedure of Pinnell and
Martin (29) as modified by Kagan and
Sullivan (30). [4,5]3H-Lysine was used to
label the chick aorta elastin as substrate for
lysyl oxidase. The lung homogenates were
adjusted to 16 mM potassium phosphate,
0.15 M NaCl, pH 7.8, with lOx buffer
and centrifuged at 24,000g. The precipi-
tates were then re-extracted with the same
volume of 16 mM phosphate buffer, 0.15
M NaCl. The phosphate buffer extracts
were then combined and frozen at -700C
until assayed.
For the assay, the precipitates were then
re-extracted 2x with the same volume of
16 mM potassium phosphate, pH 7.8, in 4
M urea as used in the phosphate buffer
extractions. The urea supernatant fractions
were combined and dialyzed overnight
against three changes of 16 mM potassium
phosphate, 0.15 M NaCl at 4°C. The pro-
tein concentration of the samples was
determined by the method of Lowry et al.
(18). The protein concentration of dia-
lyzed urea extract samples were adjusted to
the protein concentration of the lowest
sample in the group being assayed. The
same assay procedure was followed with
the phosphate buffer extracts.
Lysyloxidase assays were done in tripli-
cates except in the few cases where only
duplicates were possible. Incubations were
conducted with 1 x 106 dpm substrate and
0.9 ml of extract in a total volume of 1 ml
at 430C for 4 hr. The reaction was stopped
by adding 100 pl of 100% (w/v) TCA.
The tritiated water generated by enzyme
activity was vacuum distilled and counted
using a liquid scintillation counter
(Beckman model LS 5801). For each assay,
a 0.9-ml aliquot of pooled leftover enzyme
extracts was assayed in the presence of 0.4
mM P-aminoproprionitrile, an inhibitor of
lyslyoxidase. Controls without enzyme
were run with every assay and subtracted
from the enzyme assay values. Activity is
expressed as dpm tritiated H20 per hour
per lung.
Collagenase assays were performed
according to the procedure of Cawston and
Murphy (31). Type I collagen was purified
from rat tail tendon. The purified collagen
was labeled with 14C-acetic anhydride.
Collagenase incubations were run for 18 hr
at 37°C with 0.1 ml of lung homogenate.
Solubilization of the collagen by hamster
lung homogenates was demonstrated to be
linear over this time period (data not
shown). This activity could be abolished
with a final concentration of 10 mM
EDTA in the assay. Activity is expressed as
pg collagen solubilized per hour per lung.
Determination of Lung Collagen
Cross-links. Sufficient ice-cold saline was
added to a known amount of pulverized
lung tissue to make a 1:1 ratio of tissue to
saline. The tissue was then homogenized
for 30 sec in three bursts with a Polytron
that was set at a medium power setting. A
0.3-ml aliquot was removed and placed in
a 1.5-ml conical centrifuge tube. The sam-
ples were centrifuged for 5 min at 16,000g
and the supernatants discarded. The pre-
cipitates were washed in 1 ml 0.1 M
sodium phosphate, pH 7.2, by centrifuga-
tion three times, and resuspended in 1.0
ml of the same buffer. The supernatant
wash fractions were analyzed for hydrox-
yproline in a trial experiment and none was
detected (data not shown).
Reduction was carried out similarly to
the procedure of Fukae and Mechanic
(32). Six microliters of tritiated sodium
borohydride with specific activity of 142
mCi/mole (diluted from the original stock)
dissolved in dimethylformamide (5 mg/ml)
was added to each sample in three aliquots
5 min apart and allowed to incubate an
additional 45 min after the last addition.
The reaction was stopped by adding 0.3 ml
of glacial acetic acid. The unincorporated
radioactivity was separated from the colla-
gen by centrifugation at 16,000g and dis-
carding the supernatant fraction five times.
The pellet was transferred to a hydrolysis
tube containing 1 ml of 6 N HCl and
purged with nitrogen. Hydrolysis was car-
ried out at 1 10°C for 24 hr. The HCl was
evaporated by heating at 100°C under
nitrogen using a heating block. The sam-
ples were then resuspended in 0.3 ml water
and filtered using Rainin 0.45 pm syringe
filters. Hydroxyproline, dihydroxylysi-
nonoroleucine (DHLNL) and hydrox-
ypyridinium (OHP) were analyzed on the
same samples. Hydroxyproline content per
lung was determined using the procedure
ofWoessner (23).
Determination ofDHLNL content was
performed according to the procedure of
Reiser and Last (33). Briefly, a sample con-
taining 5 pg of hydroxyproline was injected
onto a Perkin Elmer Series 4 HPLC run-
ning in isocratic mode with 0.1 M sodium
phosphate buffer, pH 2.84, in 22% n-
propanol, and 0.3% SDS at a flow rate of
0.8 ml/min. An ultrasphere C18 column
(0.4[d]x25 cm) (Beckman, Sunnyvale, CA)
was used for the separation. Postcolumn
derivatization was carried out with a Perkin
Elmer Series 10 pump with 0.08% o-
phthalaldehyde (w/v) (Pierce Chemicals,
Rockford, IL), 0.1% P-mercaptoethanol
(v/v) in 0.3 M sodium borate buffer, pH
10.4, with a flow rate of 0.5 ml/min.
Fluorescence was monitored using a
Shimadzu model RF-535 fluorescence
detector equipped with a 12-pl flow cell.
The excitation and emission wavelengths
were 360 and 455 nm, respectively. A
Perkin Elmer LCl 100 computing integra-
tor was used to record the signal. Radio-
activity was monitored by collecting
fractions at 0.5-min intervals. Tritium con-
tent was determined by using a Beckman
model 5801 liquid scintillation counter
with a preset tritium channel.
The identity of the DHLNL was deter-
mined by its elution position just after
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arginine on the HPLC profile, as detected
by orthophthalaldehyde, of hydrolyzed
bovine achilles tendon and hydrolyzed
hamster lung. This peak identified as
DHLNL was radiolabeled when the sample
was reduced with tritiated sodium borohy-
dride. The putative DHLNL peak was pre-
sent in bovine Achilles tendon and not
present in rat tail tendon as described by
Eyre et al. (34). The radioactivity of the
DHLNL peak was converted to mmoles of
DHLNL using the procedure of Gallop et
al. (35) as modified by Reiser et al. (36).
The OHP content of the samples was
determined by the method of Eyre et al.
(34). An aliquot of each sample containing
1.5 pg of OHP was injected with a manual
injector onto the Perkin Elmer Series 4
HPLC system. The flow rate was 1.0
ml/min with 0.01 M heptafluorobutyric
acid in 16% acetonitrile as the eluent.
OHP was separated using a (0.25[d]x10
cm) Perkin Elmer Series 4 C18 HPLC col-
umn. Fluorescence was detected by a
Shimadzu model RF535 fluorescence
detector with excitation and emission
wavelengths of 294 and 395 nm, respec-
tively. The signal was recorded using the
Perkin Elmer LCI 100 Computing
Integrator. The area under the OHP peak
was determined by cutting out the peak
and weighing it.
The identity of the OHP was deter-
mined by purifying a standard from bovine
achilles tendon according to the procedure
of Eyre et al. (34). The fluorescence spec-
trum of this compound in dilute acid
matched the published spectrum for OHP
(37). Also the compound was destroyed by
overnight exposure to ultraviolet light as
reported by Koob et al (38). The putative
OHP was absent in hydrolyzed samples of
rat tail tendon as had been previously
reported (34). The molar fluorescence
yield of OHP was determined using the
method of Eyre et al. (34).
Statistical Analysis ofData
The data are expressed on a per lung basis,
which avoids the artificial lowering of the
values in bleomycin-treated animals due to
presence of proteins of extrapulmonary ori-
gin (39). However, lung DHLNL and OHP
levels were expressed as mmoles cross-link
per mole of collagen. Lung collagen con-
tent is known to increase with intratracheal
instillation of bleomycin (4). Expression of
the data on the basis of mole cross-link per
mole of collagen avoids an increase in lung
cross-link content as a result of an overall
increase in the total collagen content in the
lungs of bleomycin-treated hamsters.
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Figure 1. Effects of combined treatment with taurine
and niacin on BL-induced increases in the lung
hydroxyproline content of hamsters. Hamsters were
fed taurine (2.5%) and niacin (2.5%) in the pulverized
diet and instilled with BL intratracheally (IT) (2.5, 2.0,
and 1.5 units/5 ml/kg bw) in three consecutive doses
at weekly intervals. Twenty days after the last IT instil-
lation, hamsters were killed and their lungs processed
for the hydroxyproline assay as described in
"Materials and Methods". SA, saline control; TNSA,
taurine + niacin + saline; BL, bleomycin alone; TNBL,
taurine + niacin + bleomycin. The number of animals in
each group is shown in parenthesis below each bar
and treatment groups are indicated along the X-axis
and explained in Materials and Methods. Values are
means ± SE. *Significantly higher (p<0.05) than all
other groups.
All values are reported as the mean ±
one standard error (SE) and analyzed by
one-way analysis of variance and Fisher's
least significant difference test. A value of
p < 0.05 was considered significant.
Results
Lung Hydroxyproline Content and
Prolyl Hydroxylase Activity
Lung hydroxyproline content in various
groups of hamsters at 20 days after the last
IT instillation is shown in Figure 1.
Bleomycin significantly elevated the lung
hydroxyproline level to 194% of the saline
controls. Combined treatment with taurine
and niacin blocked the BL-induced increases
in lung hydroxyproline content. Bleomycin
alone increased the lung prolyl hydroxylase
activity to 1810% of the saline controls
(Figure 2). Likewise, combined treatment
with taurine and niacin inhibited the BL-
induced increases in lung prolyl hydroxylase
activity to the levels that were near controls.
Malondialdehyde Equivalent and SOD
Activity
Lung malondialdehyde equivalent (MDAE)
was elevated significantly by three doses of
BL instillation (Table 1). The SOD activity
in the lungs of these animals was found to
be stimulated by BL treatment (Table 1).
Treatment with taurine + niacin
Figure 2. Effects of combined treatment with taurine
and niacin on BL-induced increases in the prolyl
hydroxylase activity of hamster lungs. See legend to
Figure 1 for explanation of abbreviations and experi-
mental details. The lungs were processed for the prolyl
hydroxylase assay as described in "Materials and
Methods". The saline control activities of this enzyme
averaged 112,000 ± 5250 dpm/30 min/lung. The num-
ber of animals in each group is shown in parentheses
below each bar and treatment groups are indicated
along the X-axis and explained in Materials and
Methods. Values are means ± SE. *Significantly higher
(p< 0.05) than all other groups.
significantly diminished the BL-induced
increases in the lung MDAE, although its
level in the TNBL group was still
significantly higher than those of the SA
and TNSA groups (Table 1). As shown in
Table 1, taurine + niacin treatment pre-
vented the BL-induced increases in lung
SOD activity.
Lung Calcium Content and Poly(ADP-
ribose) Polymerase Activity
Intratracheal instillation of Bl significantly
increased lung calcium content (Table 1).
BL-induced increases in lung calcium were
decreased by the treatment with taurine and
niacin. Lung calcium content in TNBL ani-
mals was not significantly different from
that of the SA or TNSA groups (Table 1).
BL administration significantly elevated
poly(ADP-ribose) polymerase activity in
hamster lungs compared to the control
groups (SA and TNSA) (Figure 3). Taurine
and niacin treatment significantly attenu-
ated the increase in poly(ADP-ribose) poly-
merase activity in the BL-treated animals in
TNBL groups. There was no significant dif-
ference in the activity of this enzyme among
the hamsters in the SA, TNSA, and TNBL
groups.
Protein Content, Acid Phosphatase
Activity, and Cell Counts in BAL Fluid
(BALF)
The protein content and acid phosphatase
activity in the BALF supernatant of varying
groups are shown in Table 1. Intratracheal
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Table 1. Effects of combined treatment with taurine and niacin on bleomycin-induced increases in various biochemical and morphometric parameters in hamster lungs.a
Parameters SA n TNSA n BL n TNBL n
Malondialdehyde equivalent, nmole/lung 109.4± 7.0 7 109.5 ±8.9 7 211.1 ± 10.5b 9 146.4±8.1c 13
Superoxide dismutase, U/lung 400.5 ± 13.8 7 360.3 ± 12.2 7 582.2 ± 22.5b 9 385.6 ± 7.1 13
BALF supernatant protein, pg/lung) 1520 ± 95 5 1602 ± 113 5 5043 ± 619b 6 3249 ±298c 6
BALF acid phosphatase, nmole/hr/lung 235.3 ± 36.1 5 296.8 ± 66.7 5 710.7 ± 141.2b 6 380.4 ± 115.9 6
Lung total calcium, pg/lung 33.9± 1.3 6 31.7 ± 0.8 6 63.7 ± 4.1b 9 38.2± 1.6 13
Lung volume, cm3 6.72 ± 0.3b 5 5.7 0.3 5 4.7 0.2d 6 5.6 ± 0.1 6
Volume of lesions, cm3 0 5 0 5 0.92 ± 0.14b 6 0.13 ± 0.02 6
aHamsters were fed taurine (2.5%) and niacin (2.5%) in the pulverized diet and given bleomycin IT (2.5, 2.0, and 1.5 U/5 ml/kg/bw) in three consecutive doses at weekly inter-
vals. Twenty days after the last IT instillation, hamsters were killed and lung and bronchoalveolar lavage fluid (BALF) processed for various biochemical and morphometric
analysis as described in Materials and Methods. Legend for Figure 1 explains abbreviations and experimental details. Values are expressed as mean ± SE. n is the number of
animals in each group. bSignificantly higher (p<0.05) than all other corresponding groups. CSignificantly lower (p<0.05) than the corresponding BL group, but higher (p<0.05)
than corresponding SA and TNSA groups. d Significantly lower (p< 0.05) than all other corresponding groups.
Figure 3. Effects of combined treatment with taurine
and niacin on BL-induced increases in poly(ADP-ribose)
polymerase activity of hamster lungs. Legend for
Figure 1 explains abbreviations and experimental
details. The lungs were processed for the poly(ADP-
ribose) polymerase assay as described in Materials
and Methods. The number of animals in each group is
shown in parentheses below each bar and treatment
groups are indicated along the X-axis and explained in
Materials and Methods. Values are means ± SE.
*Significantly higher (p< 0.05) than all other groups.
instillations of BL significantly increased
the protein content to 332% of the SA
group, and acid phosphatase activity to
302% of the SA group. However, com-
bined treatment with taurine and niacin
significantly decreased the BL-induced
increases of BALF supernatant protein to
214% of the SA group, and acid phos-
phatase activity to 162% of the SA group.
Although the protein content of TNBL
was still significantly higher than that of
SA and TNSA groups, there were no
significant differences in BALF supernatant
acid phosphatase activity among SA,
TNSA, and TNBL groups (Table 1).
The number of total cells and the
absolute number of differential cells in the
BALF of the four treatment groups after
intratracheal instillation of saline or BL are
summarized in Table 2. As compared with
the SA group, the numbers of total cells,
neutrophils, macrophages, and lympho-
cytes in the BL group were increased by
3.1-, 245-, 2.5-, and 8.0-fold. In contrast,
as compared with the SA group, the num-
bers of total cells, neutrophils, macro-
phages, and lymphocytes in the TNBL
group were increased by only 2.1-, 30.3-,
2.0-, and 4.1-fold. The total numbers of
neutrophils, monocytes, macrophages, and
lymphocytes recovered in the BALF of
TNBL groups were not significantly higher
than those of the SA and TNSA groups in
most cases. Taurine and niacin significantly
suppressed the BL-induced increases of
neutrophils in the airways to such an
extent that there were no significant differ-
ences in the number of BALF neutrophils
among the hamsters in the SA, TNSA, and
TNBL groups. There were remarkable
increases in the BALF eosinophils in the
BL groups and fewer BALF eosinophils in
the TNBL groups than in the BL groups,
but the differences in the numbers of
BALF eosinophils among all 4 groups were
not statistically significant (Table 2).
Morphology and Morphometry
The biochemical and cell data in the BALF
correlated well with morphologic and
morphometric observations. Normal pul-
monary parenchymal tissue was observed
in SA and TNSA hamsters with normal
lung volume and essentially no lesions. In
contrast, hamsters that received BL alone
had decreased lung volume associated with
a patchy alveolitis and multifocal intersti-
tial fibrosis that comprised about 20% of
the total parenchyma (Table 1, Figure 4A).
The lungs of hamsters in the BL group had
thickened interalveolar septa and
inflammatory cells in adjacent airspaces.
The focal lung lesions were randomly dis-
tributed throughout pulmonary acini. In
half of the hamsters, foci of fibrotic consol-
idation were observed. In diffuse lesions,
alveolar airspaces were often obliterated by
organized connective tissue. These regions
stained heavily with the sirus red stain.
These fibrotic regions contained abundant
fibroblasts and numerous inflammatory
cells, and were usually adjacent to necrotic
epithelial cells. Even thick septa in BL-
treated hamster lungs contained more
inflammatory cells and necrotic epithelial
cells than thick septa in the lungs ofTNBL
hamsters. Hamsters in the TNBL groups
Table 2. Total and differential cell counts in bronchoalveolar lavage fluid intratracheal instillation of bleomycin or saline with or without combined treatment with taurine and niacin.a
Treatment Total cells, Neutrophils, Monocytes, Macrophage, Lymphoc' tes, Eosinophils,
group(n) x104 xl 04 x104 x104 x10 x104
SA (5) 2.76 ± 0.22 0.37 ± 0.37 0 ± 0 2.66 ± 0.23 0.77 ± 0.12 1.79 ± 1.22
TNSA (5) 2.63 ± 0.24 3.99 ± 1.39 0.22 ± 0.22 2.55 ± 0.24 0.39 ± 0.10 0.18 ± 0.18
BL (6) 8.63 ± 1.41 90.5 ± 40.80c 5.05 ± 1.86 6.75 ± 1.17 6.19 ± 3.18 30.2 ± 25.30
TNBL (6) 5.76 ± 1.12 11.2 ± 3.29 3.29 ± 1.70 5.24 ± 0.96 3.18 ± 0.94 5.24 ± 4.93
'Hamsters were fed taurine (2.5%) and niacin (2.5%) in the pulverized diet and given bleomycin IT (2.5, 2.0, and 1.5 U/5 ml/kg bw) in three consecutive doses at weekly inter-
vals. Twenty days after the last IT instillation, bronchoalveolar lavage was carried out and total and differential cell counts analyzed as described in Materials and Methods.
Legend for Figure 1 explains abbreviations and experimental details. The number of animals in each group is shown in parentheses. Values are expressed as mean ± SE.
bSignificantly higher (p< 0.05) than corresponding SA and TNSA groups. CSignificantly higher (p < 0.05) than all other corresponding groups.
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Figure 4. (A) A representative photomicrograph of pulmonary proximal acini from a hamster treated with bleomycin intratracheally (IT) and without taurine and niacin treat-
ment (BL). Note the multifocal thickening of interalveolar septa by mononuclear phagocytes and fibroblasts (arrow). An arrow in the inset marks a fibroblast with adjacent fib-
rin in an alveolar space. (B) A photomicrograph of pulmonary proximal acini from a hamster treated with bleomycin IT and taurine (2.5%) and niacin (2.5%) in the diet (TNBL).
Note the focus of thickened interalveolar septa that was only occasionlly observed (arrow). The subpleurally located lesion showed primarily mononuclear phagocytes (inset).
B, distal bronchus; Ad, alveolar duct; A, arteriole. Paraffin sections, hematoxylin and eosin x 77, inset x 390.
3 3000 --
ci
D 2400
a) 1B000
C 1200
0->, 600
7)J
I1 °
Tim
I
- SA
BL
= TN3ei
= TNSA
(71 (9) (9) (6) (7)(8) 00) (5) (7) (8) (9) (6)
Week 1 4 8
(e After Bleomycin Treatment
Figure 5. Effects of combined treatment with taurine
and niacin on BL-induced increases in the hydroxy-
proline content of hamster lungs. The animals were
killed at 1, 4, and 8 weeks after the last instillation and
their lungs processed for the hydroxyproline assay as
described in Materials and Methods. Legend for Figure
1 explains abbreviations and experimental details. The
number of animals in each group is shown in parenthe-
ses below each bar and treatment groups by different
bars. Each value represents mean ± SE. *Week 1: BL is
significantly higher (p< 0.05) than SA, TNBL, and TNSA
groups. **Week 4: BL is significantly higher (p<0.01)
than SA, TNBL, and TNSA groups. **Week 8: BL is
significantly higher (p< 0.01) than SA, TNBL, and TNSA
groups.
showed little to no alveolitis and interstitial
fibrosis with infrequent focal lesions of
interstitial thickening with aggregations of
mononuclear phagocytes (Figure 4B).
Thickened septa, although infrequently
observed, had numerous capillaries and
some inflammatory cells. Necrotic epithe-
lial cells were seldom observed adjacent to
thick septa in TNBL hamsters. The com-
bined treatment with taurine and niacin
effectively prevented the BL-induced
increases in fibrotic lesion to less than
2.3% of the pulmonary parenchyma that
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Figure 6. Effects of combined treatment with taurine
and niacin on BL-induced increases in the lung lysyl
oxidase activity of hamster. Legend for Figure 1
explains experimental details and abbreviations for
treatment groups. Lysyl oxidase activity was measured
as described in Materials and Methods. The number of
animals in each group is shown in parentheses below
each bar and treatment groups by different bars. Each
value represents mean ± SE. *Week 1: BL is signifi-
cantly higher (p<0.01) than SA, TNBL, and TNSA
groups. *Week 4: BL is significantly higher (p<0.01)
than SA, TNBL, and TNSA groups. Week 8: there are no
statistically significant differences among the four
groups.
were not significantly different from those
in the SA and TNSA groups (Table 1).
and
Hydroxyproline content per lung at 1, 4,
and 8 weeks after the last dose of BL or
saline instillation is shown in Figure 5.
Bleomycin treatment in the control diet
animals significantly increased the total
lung hydroxyproline content to 138, 156,
and 160% of the saline instilled control diet
group at 1, 4, and 8 weeks, respectively. The
increase in hydroxyproline content seen in
the BL group was prevented by dietary
administration of taurine and niacin at all
three time points. Taurine-niacin treatment
did not significantly decrease lung collagen
content in the saline-instilled group relative
to the saline-instilled group on the control
diet at any of the three time points.
The lung lysyloxidase activity in differ-
ent groups of hamsters is summarized in
Figure 6. The activity in the BL group was
significantly increased to 158 and 191% of
the SA group at 1 and 4 weeks, respec-
tively. However, taurine-niacin fed in the
diet completely blocked bleomycin-
induced increases in the lung lysyloxidase
activity of the hamsters in the TNBL
groups. Although lysyloxidase activity in
the BL group was elevated at 8 weeks after
the last bleomycin instillation, it was not
significantly different from any other groups
at that time point. The taurine-niacin in
diet per se had no effect on the lysyloxidase
activity in the TNSA groups.
Type I collagenase activity at 1, 4, and
8 weeks after the last bleomycin instillation
is shown in Figure 7. The collagenase
activity in the BL group was significantly
increased to 165 and 180% of the SA
group at 1 and 4 weeks after the last dose of
bleomycin, respectively. The taurine-niacin
fed in the diet abolished bleomycin-
induced increases in the collagenase activity
in the TNBL group both at 1 and 4 weeks.
In fact, the activity in this group tended to
be lower than the SA group at all three
points. There was no significant difference
in collagenase activity between the SA and
BL groups at 8 weeks and the activity in
the TNBL group was significantly higher
than that of the TNSA group.
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Figure 7. Effects of combined treatment with taurine
and niacin on BL-induced increases in the lung collage-
nase activity of hamsters. Legend for Figure 1 explains
experimental details and abbreviations for treatment
groups. Collagenase activity was measured as
described in Materials and Methods. The number of
animals in each group is shown in parentheses below
each bar and treatment groups by different bars. Each
value represents mean ± SE. *Week 1: BL is signifi-
cantly higher (p<0.01) than SA, TNBL, and TNSA
groups. **Week 4: BL is significantly higher (p<0.03)
than SA, TNBL, and TNSA groups. Week 8: TNBL is
significantly higher (p. 0.04) than TNSA group.
Lung Coliagen Cross-link Content
DHLNL content per mole of lung collagen
at 1, 4, and 8 weeks after the last bleomycin
or saline instillation is shown in Figure 8.
DHLNL in the BL group was significantly
increased to 146% of the SA group at the
four week time point. There were no
significant differences among the four
groups at the 1- and 8-week time points.
Taurine-niacin treatment prevented the
bleomycin-induced increase in DHLNL
content per mole of collagen at 4 weeks.
OHP content per mole of lung collagen
at 1, 4, and 8 weeks after the last BL or
saline instillation is shown in Figure 9. At
the 1- and 4-week time points, there were
no statistically significant differences
among the four groups. However, the
OHP content in the BL group was 131%
of the values of the SA, TNBL, and TNSA
groups (p< 0.05) at 8 weeks.
Discussion
In the present study, we have demonstrated
that dietary supplementation with taurine
and niacin abolished the BL-induced lung
collagen accumulation in hamsters. One of
the underlying mechanisms for the patho-
genesis of BL-induced lung injury includes
the generation of reactive oxygen species
(ROS)(40). It is generally believed that
under aerobic conditions an intracellular
BL-Fe2+ complex undergoes a cyclic oxida-
tion-reduction in the presence of a reduc-
ing equivalent (41). This complex
functions as a minienzyme, catalytically
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Figure 8. Effects of combined treatment with taurine
and niacin on BL-induced increases in lung dihydroxy-
lysinonoroleucine (DHLNL mmole/mole of collagen)
content in hamsters. See legend to Figure 1 for experi-
mental details and explanation of abbreviations for
treatment groups. Lung DHLNL was measured as
described in Materials and Methods. The number of
animals in each group is shown in parentheses below
each bar and treatment groups by different bars. Each
value represents mean ± SE. Week 1: there are no sta-
tistically significant differences among the four groups
(p> 0.05). *Week 4: BL is significantly higher (p< 0.02)
than SA, TNBL, and TNSA groups. Week 8: there are
no statistically significant differences among the four
groups (p> 0.05).
reducing molecular oxygen leading to gen-
eration of various types of ROS. The
mechanism by which the dietary supple-
mentation with taurine and niacin offered
protection against BL-induced lung fibrosis
is not clearly understood. However, the
results of this study suggest that the
beneficial effect of the combined treatment
with taurine and niacin may be attributed
to their ability to suppress the BL-induced
increases in the lung collagen reactivity and
offer protection against the deleterious
effects ofROS generated by BL.
The following lines of evidence suggest
that the dietary supplementation with tau-
rine and niacin inhibits the lung collagen
reactivity in the BL-hamster model of lung
fibrosis. First, dietary supplementation
with taurine and niacin inhibited the BL-
induced increases in the lung prolyl
hydroxylase activity and a decrease in the
activity of this enzyme paralleled a marked
reduction in the lung collagen accumula-
tion. It has been demonstrated by several
investigators that the accumulation of col-
lagen in the BL-rodent model of lung
fibrosis usually follows the increase in the
lung prolyl hydroxylase activity (24,42).
The prolyl hydroxylase catalyzed hydroxy-
lation of proline is a critical posttranslational
event in the processing of mature collagen
(43). A reduction in BL-induced increases
in prolyl hydroxylase activity would allow
the deposition of a more pliable and solu-
ble form of collagen that is more suscepti-
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Figure 9. Effects of combined treatment with taurine
and niacin on BL-induced increases in the lung
hydroxypyridinium (OHP mmole/mole of collagen) con-
tent in hamsters. Legend for Figure 1 explains experi-
mental details and abbreviations for treatment groups.
OHP was measured as described in Materials and
Methods. The number of animals in each group is
shown in parentheses below each bar and treatment
groups by different bars. Each value represents mean ±
SE. Week 1: there are no statistically significant differ-
ences among the four groups (p>0.05). Week 4: there
are no statistically significant differences among the
four groups (p>0.05). *Week 8: BL is significantly
higher (p< 0.05) than SA, TNBL, and TNSA groups.
ble to degradation by collagenases than the
mature collagen fibers.
Second, dietary supplementation with
taurine and niacin inhibited the BL-
induced increases in the lung lysyl oxidase
activity. Lysyloxidase oxidatively deami-
nates peptidyl lysine and hydroxylysine
residues in the collagen molecule (29,44).
The deamination is not only an obligatory
but it possibly represents a rate-limiting
step in collagen cross-linking. The lysyloxi-
dase activity is shown to be increased in
BL-induced lung fibrosis (45) and treat-
ment with ,B-aminopropionitrile was found
to block both the BL-induced increases in
the lung lysyloxidase activity and collagen
accumulation (46,47). Our findings are
very similar since dietary intake of
taurine-niacin blocked both bleomycin-
induced increases in the lung lysyloxidase
activity at 1 and 4 weeks and the collagen
accumulation at 1, 4, and 8 weeks after the
last dose of bleomycin. It appears that the
increased lung lysyl oxidase activity in BL-
instilled animals, as found in this as well as
in other studies, may be essential for the
accumulation of collagen in the lung and
that inhibition of this enzyme by dietary
intake of taurine-niacin, as reported in this
study, may constitute another possible
mechanism for their antifibrotic effect.
The mechanisms as to how BL instilla-
tion increases the lung lysyloxidase activity
and how dietary intake of taurine-niacin
prevents this increase are not known. It is,
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however, possible that taurine and niacin
either somehow decrease the synthesis
and/or increase the inactivation of this
enzyme protein. It is also possible that tau-
rine-niacin treatment may simply block or
ameliorate the BL-induced initial tissue
damage and this then prevents the
inflammatory events reaching the intensity
that is essential for generation of an array
of mediators involved in triggering an
increase in the lysyloxidase activity.
Dietary supplementation with taurine
and niacin also caused a marked reduction
in the BL-induced increases in the lung col-
lagenase activity. The role of collagenase in
the accumulation of collagen in the fibrotic
lung is unclear. Laurent and McAnulty (48)
and others have suggested that decreased
degradation is in part responsible for the
accumulation of collagen seen in the fibrotic
lungs. Phan et al. (49) found a marked
decrease in the breakdown of collagen in
vitro in a single-dose bleomycin model of
lung fibrosis in rats. Selman et al. (50)
found that the release of hydroxyproline
from lung biopsy samples from 11 patients
suffering from idiopathic pulmonary fibrosis
was markedly decreased in vitro relative to
controls. Montano et al. (51) also found
lowered hydroxyproline release from lung
biopsy samples taken from patients with
pulmonary fibrosis in vitro.
In contrast to these findings, a number
of researchers have found that collagen
degradation is increased in pulmonary
fibrosis. Elevated Type I collagenase activ-
ity was found in BALF from 15 of 21
patients with pulmonary fibrosis (52).
Christner et al. (53) found increased Type
I collagenase activity in the BALF of 12 of
17 patients with idiopathic pulmonary
fibrosis. The BALF in rats intratracheally
instilled with bleomycin contained elevated
levels ofType I collagenase (54).
Our own results indicate that Type I
collagenase activity was elevated in the BL
group at the 1- and 4-week time points
and declined to the level of the SA group
by 8 weeks. The rise and decline in collage-
nase activity following the last BL instilla-
tion roughly paralleled the increase and
subsequent decline in inflammatory cells
over time, as found by Zia et al. (14). The
increased collagenase activity in BL-
instilled hamster lung is probably due in
part to collagenase secreted by neutrophils
(55) and alveolar macrophages (56). It
should be noted that alveolar macrophages
isolated from single-dose, BL-instilled rats
showed an increase in secreted collagenase
activity relative to control animals (54).
Bleomycin instillation may well cause
an increase in extracellular collagenolytic
peptides. A role for an increased amount of
collagenolytic peptides is suggested by the
work of several investigators. Malone et al.
(57) found that collagenase digests ofType
I collagen can recruit peripheral mononu-
clear cells. Riley et al. (47) found that
intratracheal instillation of collagen frag-
ments could cause an influx of neutrophils.
Postlethwaite et al. (58) found Type I, II,
and III collagens, collagen-derived pep-
tides, and tripeptides with hydroxyproline
were chemotactic to dermal fibroblasts. It
is possible that the role of extracellular col-
lagenolytic peptides during the fibrotic
process is to amplify and sustain the
inflammatory response, as has been sug-
gested by Crouch (1).
Another line of evidence that dietary
supplementation with taurine and niacin
suppressed the BL-induced increases in the
lung collagen reactivity was a marked
diminution of lung collagen cross-links in
the TNBL group. We had postulated that
taurine and niacin somehow could be
involved in blocking the normal process of
Schiff base formation between residues of
hydroxyallysine and hydroxylysine, thus
preventing formation of DHLNL. This
mechanism has been suggested for the
inhibitory effect of penicillamine on colla-
gen cross-link formation (59). However,
other mechanisms are now thought to play
a major role in inhibiting the formation of
collagen cross-links (60,61). If DHLNL
formation were blocked, the formation of
mature stable cross-link OHP would also
be subsequently blocked. There is good
evidence that mature cross-linked collagen
does not turn over in either the BL-induced
fibrotic lung or the normal lung (62,63).
Thus, a blockage in cross-link formation
by dietary supplementation with taurine
and niacin could at least, in part, be
responsible for minimizing the BL-induced
accumulation of collagen in the lung since
collagen deficient in cross-links is generally
more susceptible to turnover than cross-
linked collagen.
In addition to a diminution of collagen
reactivity, taurine and niacin are known to
possess other beneficial effects that protect
the tissue against the oxidant-induced tis-
sue damage. For instance, the membrane-
stabilizing antioxidant ROS and HOCI
scavenging properties of taurine seem to be
somehow involved in its protective effect
(64-68). BL-induced pulmonary toxicity is
usually attributed to the generation of
ROS (40) and their involvement in the
pulmonary toxicity is reflected by the
increase in lung SOD activity as a defense
mechanism to protect the tissue against the
deleterious effects of superoxide radicals
(24,69). In the present study, dietary sup-
plementation with taurine and niacin
significantly inhibited the BL-induced
increase of lung SOD activity. This indi-
cates that taurine and/or niacin may pre-
vent the initial BL-induced production of
ROS or block their injurious effects by
virtue of the taurine's antioxidant property.
Several laboratories, including our own,
have demonstrated that BL-induced acute
inflammatory phase is always associated
with an excessive accumulation of neu-
trophils in vascular, interstitial, and
intraalveolar compartments of the lung
(70). The activated neutrophils by virtue
of the enzyme myeloperoxidase are known
to oxidize halides Cl-, Br-, or F to their
corresponding hypohalous acid in a reac-
tion involving H202 (71). The biocidal
property of HOCI in oxidizing a variety of
biologically significant substances is well
known. The beneficial effect of the com-
bined treatment with taurine and niacin
against BL-induced lung damage may also
be attributed to a decreased influx of neu-
trophils in the various compartments of the
lung as well as to the ability of taurine to
act as a trap for HOCI. Recently, it has been
demonstrated that of all the amino acids,
taurine was the most effective inhibitor of
HOCI-induced lysis of erythrocytes (72).
Thus, it is possible that taurine could be
effective in preventing the biomembrane
damage caused by BL. This then also
would explain why the BL-induced
increases in pulmonary vascular permeabil-
ity and acid phosphatase activity of the
BALF were markedly suppressed by the
combined treatment with taurine and
niacin.
The ability of taurine to prevent an
excess influx of Ca2+ by its membrane sta-
bilizing effect might have also played a key
role in ameliorating BL-induced lung
fibrosis. This hypothesis draws support
from two lines of evidence: a) BL-induced
lung fibrosis is always associated with an
intracellular overload of Ca2+ (73); and b)
biochemical (65,67) and morphologic
findings (74) provided by other investiga-
tors suggest that taurine does indeed pre-
vent an excess influx of Ca2+. In the
presence of an excessive amount of intra-2+cellular Ca , the ability of mitochondria
to synthesize ATP is impaired, and Ca2+
accumulates at the inner surface of the cell
membrane, activating the membrane-
bound enzymes including proteases and
phospholipases that in turn damage the cell
membrane leading to cell death.
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Calcium also stimulates phospholipase-
A2, a rate-limiting enzyme, in the metabo-
lism of arachidonic acid. Metabolites of
arachidonic acid appear to be involved in
the BL-induced lung fibrosis (75).
Activation of PIA2 stimulates the peroxi-
dation of membrane lipids (76) that is
measured by the amount of MDAE. The
generation of MDAE, in addition to being
an index of lipid peroxidation, also reflects
DNA damage (77). A significant suppres-
sion in BL-induced increases in the lung
MDAE by combined treatment with tau-
rine and niacin as reported at this confer-
ence indicates that this treatment might
have inhibited BL-induced lipid peroxida-
tion and DNA damage. This is not surpris-
ing since taurine and niacin are known to
inhibit lipid peroxidation (67,78) and
DNA damage (79), respectively.
The beneficial effect of niacin against
paraquat-induced lung toxicity has been
previously reported (80). It is generally
believed that niacin offers protection
against tissue damage caused by a variety of
oxidants by virtue of its ability to increase
intracellular level of NAD and to inhibit
overactivation of poly(ADP-ribose) poly-
merase (79,81). An overstimulation of this
chromosomal enzyme leads to intracellular
depletion ofNAD (82). This hypothesis is
consistent with our earlier findings that IT
instillation of BL increased the lung
poly(ADP-ribose) polymerase activity and
caused a marked depletion of NAD (28).
This will explain why the combined treat-
ment with taurine and niacin markedly
suppressed the BL-induced overstimulation
of poly(ADP-ribose) polymerase, and pre-
sumably allowed an adequate availability of
NAD, as reported in the present study.
The availability of NAD would maintain
vital cell functions, including the DNA
repair of injured lung epithelium. This
hypothesis is further supported by our
recent finding that the daily treatment with
niacin in BL-treated hamsters not only
caused significant increases in the lung levels
of NAD and ATP, but it also minimized
the lung toxicity at 10 and 14 days follow-
ing a single IT instillation of bleomycin
(83). It is believed that the proliferation of
interstitial cells in the lung are normally
hampered by the intact epithelial cells;
under normal conditions, the lung injury is
repaired (84). However, if the injured
epithelial cells remain unrepaired, it would
trigger the proliferation of interstitial cells
leading to an excessive synthesis and depo-
sition of collagen in the lung (85,86). Our
data suggest that the combined treatment
with taurine and niacin helps repair the
BL-induced injury of epithelium and thus
minimizes the interstitial cell proliferation
and subsequent build-up of collagen.
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